Patents by Inventor Herbert Kogler

Herbert Kogler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8268775
    Abstract: The disclosure relates to compounds of the formula (I): wherein R1, R2, R3, and R4 are as defined in the disclosure, or a pharmaceutically acceptable salt thereof; which is formed by the microorganism ST 201196 (DSM 18870); the use thereof for the treatment and/or prophylaxis of fungal disorders; medicaments containing a compound of formula (I); processes for production thereof; and the microorganism ST 201196 (DSM 18870).
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: September 18, 2012
    Assignee: Sanofi
    Inventors: Holger Hoffmann, Christine Klemke-Jahn, Dietmar Schummer, Herbert Kogler
  • Publication number: 20110306563
    Abstract: The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C1-C6)-alkyl, NH2 or NH—(C1-C6)-alkyl, or X and Y together form a group —O— or wherein X and Y together form a further bond between the C atoms to which they are attached; R1 and R2 independently of one another are H, Cl or Br; R3 is H,(C1-C6)alkyl, C(?O)—(C1-C6)-alkyl or (C1-C6)-alkylene-NH—(C1-C6)-alkyl; R4 is H, (C1-C6)-alkyl or C(?O)—(C1-C6)-alkyl, and R5 is methyl or ethyl; or a physiologically tolerable salt of a compound of the formula (I), for the treatment and/or prophylaxis of cancer diseases, a pharmaceutical composition for the treatment and/or prophylaxis of cancer diseases comprising a compound of the formula (I), a compound of the formula (I) and a process for the preparation of the compound (I).
    Type: Application
    Filed: December 10, 2009
    Publication date: December 15, 2011
    Applicant: SANOFI
    Inventors: Holger Hoffmann, Michael Caspers, Dietmar Schummer, Herbert Kogler, Christine Klemke-Jahn
  • Publication number: 20100256049
    Abstract: The disclosure relates to compounds of the formula (I): wherein R1, R2, R3, and R4 are as defined in the disclosure, or a pharmaceutically acceptable salt thereof; which is formed by the microorganism ST 201196 (DSM 18870); the use thereof for the treatment and/or prophylaxis of fungal disorders; medicaments containing a compound of formula (I); processes for production thereof; and the microorganism ST 201196 (DSM 18870).
    Type: Application
    Filed: December 17, 2009
    Publication date: October 7, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Holger HOFFMANN, Christine KLEMKE-JAHN, Dietmar SCHUMMER, Herbert KOGLER
  • Patent number: 7019028
    Abstract: The invention relates to compounds of the formula (I) process for their preparation starting from the plant Beilschmiedia fulva, PLA 101037, and the use thereof for producing a medicament, in particular for the treatment of allergic disorders, of asthmatic disorders, of inflammatory concomitant symptoms of asthma and/or of diseases which can be treated by inhibiting c-maf and NFAT.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: March 28, 2006
    Assignees: Aventis Pharma Deutschland GmbH, Aventis Pharmaceuticals Inc.
    Inventors: Claudia Eder, Herbert Kogler, Sabine Haag-Richter
  • Patent number: 6933298
    Abstract: Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: August 23, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Klaus-Ulrich Weithmann, Jörg Habermann, Herbert Kogler, Reinhard Kirsch, Volkmar Wehner
  • Patent number: 6818667
    Abstract: The present invention relates to novel compounds of the formula I in which R(1), R(2), R(3) and R(4) are, independently of each other, hydrogen or an alkyl radical. The compounds of the formula I are inhibitors of KDR kinase and, due to their antiangiogenic effect, are suitable for preventing and/or treating malignant diseases. The compounds of the formula I can be obtained by fermenting the microorganism Eurotium echinulatum Delacroix (DSM 13872) or by chemically derivatizing the compounds which are obtained after fermenting said microorganism. The invention consequently also relates to a process for preparing the compounds of the formula I, to the use of the compounds of the formula I for preparing a pharmaceutical for treating malignant diseases and diseases which can be treated by inhibiting KDR kinase, and also to pharmaceutical preparations which have a content of at least one compound of the formula I.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: November 16, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Claudia Eder, Herbert Kogler, Luigi Toti
  • Publication number: 20040138313
    Abstract: The invention relates to compounds of the formula (I) 1
    Type: Application
    Filed: July 25, 2003
    Publication date: July 15, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Claudia Eder, Herbert Kogler, Sabine Haag-Richter
  • Publication number: 20030229103
    Abstract: Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula I. These compounds are found to possess the property of selectively inhibiting collagenase (MMP). They may therefore be useful in prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13.
    Type: Application
    Filed: December 9, 2002
    Publication date: December 11, 2003
    Inventors: Klaus-Ulrich Weithmann , Jorg Habermann , Herbert Kogler , Reinhard Kirsch , Volkmar Wehner
  • Patent number: 6627604
    Abstract: The invention relates to novel peptide derivatives, called memno peptides, of the formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8 and (A)n have the meaning herein, obtainable by cultivation of Memnoniella echinata FH2272, DSM 13195 or mutants and variants of this, a process for their preparation and the use of the compounds as pharmaceuticals, for example against cardiac insufficiency.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: September 30, 2003
    Assignee: Aventis Pharma Deutschland, GmbH
    Inventors: Laszlo Vertesy, Herbert Kogler, Astrid Markus, Matthias Schiell
  • Publication number: 20030125375
    Abstract: The present invention relates to novel compounds of the formula I 1
    Type: Application
    Filed: June 26, 2002
    Publication date: July 3, 2003
    Inventors: Claudia Eder, Herbert Kogler, Luigi Toti
  • Patent number: 6579903
    Abstract: The invention relates to compounds of formula I and of formula II in which R1, R2, R3, R4, R5, X1, X2, X3, X4, X5 and Y are defined in the specification. The compounds of formulae I and II inhibit cyclin-dependent kinases (CDKS) and other kinases (KDR), have cytostatic actions, and are suitable for treating tumors. The compounds of formulae I and II are obtainable by extracting the plant Uvaria klaineri, PLA 100484, by cell cultures of the plant Uvaria klaineri, or by chemical synthesis. The invention relates to a method for preparing the compounds of formulae I and II, to the use of the compounds for producing a pharmaceutical for the treatment of malignant disorders and of diseases which may be treated by inhibition of CDKs and KDR, and also to pharmaceutical compositions comprising at least one compound of the formula I or II.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: June 17, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Sabine Haag, Herbert Kogler, Ziyu Li, Laszlo Vertésy
  • Publication number: 20020103389
    Abstract: The invention relates to compounds of formula I 1
    Type: Application
    Filed: December 4, 2001
    Publication date: August 1, 2002
    Inventors: Sabine Haag, Herbert Kogler, Ziyu Li, Laszlo Vertesy
  • Publication number: 20010031857
    Abstract: The invention relates to novel peptide derivatives, called memno peptides, of the formula (I): 1
    Type: Application
    Filed: February 28, 2001
    Publication date: October 18, 2001
    Inventors: Laszlo Vertesy, Herbert Kogler, Astrid Markus, Matthias Schiell
  • Patent number: 6297043
    Abstract: The present invention relates to a compound named Mumbaistatin, its pharmaceutically acceptable salts and derivatives, a process for its production, and its use as a pharmaceutical. Mumbaistatin is obtainable by cultivation of the microorganism HIL-008003 (DSM 11641). Mumbaistatin is a glucose-6-phosphate translocase inhibitor and can be used in the treatment of diabetes mellitus. The present invention further relates to a process for the production of Mumbaistatin, to the microorganism HIL-008003 (DSM 11641), to the use of Mumbaistatin and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use in the treatment of diabetes mellitus, and to pharmaceutical compositions comprising Mumbaistatin or a pharmaceutically acceptable salt or derivative thereof.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: October 2, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Nirogi Venkata Satya Ramakrishna, Keshavapura Hosamane Sreedhara Swamy, Erra Koteswara Satya Vijaya Kumar, Manoj Maniram Singh Kushwaha, Sridevi Kota, Mythili Raman, Swati Dhananjay Tare, Sunil Kumar Deshmukh, Dietmar Schummer, Michael Kurz, Herbert Kogler
  • Patent number: 6221844
    Abstract: The invention relates to novel peptides, namely texenomycins, from Scleroderma texense, a process for their preparation and their use as pharmaceuticals, in particular as antimycotics. The texenomycins according to the present invention are distinguished in particular by the amino acid sequence I in which FS is an oxo fatty acid radical, Aib is aminoisobutyric acid and Arg-ol=argininol.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: April 24, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heike Stump, Wilhelm Stahl, Joachim Wink, Astrid Markus, Herbert Kogler, Jürgen Backhaus
  • Patent number: 6166070
    Abstract: Kodaistatins A and B, compounds of the molecular formula C.sub.35 H.sub.34 O.sub.11, and Kodaistatins C and D, compounds of the molecular formula C.sub.35 H.sub.34 O.sub.12, have antidiabetic activity.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: December 26, 2000
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Nirogi Venkata Satya Ramakrishna, Keshavapura Hosamane Sreedhara Swamy, Erra Koreswara Satya Vijayakumar, Suresh Rudra Nadkarni, Kenia Jayvanti, Andreas Herling, Herbert Kogler, Laszlo Vertesy, Rajan Mukund Panshikar, Kota Sridevi, Mythili Raman, Roda Maneck Dalal
  • Patent number: 6022851
    Abstract: The present invention relates to a novel lantibiotic having the formula NH.sub.2 --R-actagardine, where NH.sub.2 --R is the radical of the amino acid alanine, which is formed by the microorganism Actinoplanes liguriae, DSM 11797 or Actinoplanes garbadiensis, DSM 11796 during fermentation, chemical derivatives of the lantibiotic, a process for its preparation and the use of the lantibiotics as pharmaceuticals.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: February 8, 2000
    Assignee: Hoechst Marion Roussel Deutschland, GmbH
    Inventors: Laszlo Vertesy, Herbert Kogler, Matthias Schiell, Joachim Wink
  • Patent number: 5571701
    Abstract: Balhimycin, a compound of the molecular formula C.sub.66 H.sub.73 C1.sub.2 N.sub.9 0.sub.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 5, 1996
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Suresh R. Nadkarni, Sugata Chatterjee, Mahesh V. Patel, Kalvanapuram R. Desikan, Erra K. S. Vijayakumar, Bimal N. Ganguli, Jurgen Blumbach, Hans-Wolfram Fehlhaber, Herbert Kogler
  • Patent number: 5459141
    Abstract: Compounds 31668P and 31668U, a process for their production and their use.Compound 31668P and compound 31668U with the formulae ##STR1## have an antibiotic and an antitumor action.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: October 17, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Laslo Vertesy, Joachim Betz, Hans-Wolfram Fehlhaber, Matthias Helsberg, Herbert Kogler, Michael Limbert, Dieter-Andreas Sukatsch, Ramaiyer R. Chandran, Bimal N. Ganguli
  • Patent number: 5451570
    Abstract: Balhimycin, a compound of the molecular formula C.sub.66 H.sub.73 Cl.sub.2 N.sub.9 O.sub.24, is a novel Glycopeptide antibiotic and has the following structure (SEQ. ID. No.
    Type: Grant
    Filed: December 30, 1992
    Date of Patent: September 19, 1995
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Suresh R. Nadkarni, Sugata Chatterjee, Mahesh V. Patel, Kalvanapuram R. Desikan, Erra K. S. Vijayakumar, Bimal N. Ganguli, Jurgen Blumbach, Hans-Wolfram Fehlhaber, Herbert Kogler